Advanced search
Publication Cover
Expert Opinion on Drug Discovery Volume 1, 2006 - Issue 4
Submit an article Journal homepage
80
Views
8
CrossRef citations to date
0
Altmetric
Editorial

Antisense oligonucleotide technologies in drug discovery

Tarek Aboul-Fadl Professor of Pharmacuetical Medicinal Chemistry, Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt. [email protected]; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia
Pages 285-288 | Published online: 06 Sep 2006

Bibliography

  • HOPKINS AL GROOM CR: The druggable genome. Nat. Rev. Drug Discov. (2002) 1:727-730.
  • WAHLESTEDT C: Natural antisense and noncoding RNA transcripts as potential drug targets. Drug Discov. Today (2006) 11(11/12):503-508.
  • URBAN E, NOE CR: Structural modifications of antisense oligonucleotides. Il Farmaco (2003) 58:243-258.
  • TAMM I, DORKEN B, HARTMANN G: Antisense therapy in oncology: new hope for an old idea. Lancet (2001) 358:489-497.
  • TANAKA M, NYCE J: Respirable antisense oligonucleotides: a new drug class for respiratory disease. Respir. Res. (2001) 2:5-9.
  • DA ROS T, SPALLUTO G, PRATO M, SAISON-BEHMOARAS T, BOUTORINE A, CACCIARI B: Oligonucleotides and oligonucleotide conjugates: a new approach for cancer treatment. Curr. Med. Chem. (2005) 12:71-88.
  • ABOUL-FADL T: Sense oligonucleotides: the state of the art. Curr. Med. Chem. (2005) 12:2193-2214.
  • CHEN X, DUDGEON N, SHEN L, WANG JH: Chemical modification of gene silencing oligonucleotides for drug discovery and development. Drug Discov. Today (2005) 10(8):578-593.
  • TAYLOR MF: Emerging antisense technologies for gene functionalization and drug discovery. Drug Discov. Today (2001) 6(15 Suppl.): S97-S101.
  • VIDAL L, BLAGDEN S, ATTARD G, DE BONO J: Making sense of antisense. Eur. J. Cancer (2005) 41:2812-2818.
  • AGRAWAL S, KANDIMALLA ER: Antisense therapeutics: is it as simple as complementary base recognition? Mol. Med. Today (2000) 6:72-81.
  • HUBER LC, DISTLER O, GAY RE, GAY S: Antisense strategies in degenerative joint diseases: Sense or nonsense? Adv. Drug Deliv. Rev. (2006) 58: 285-299.
  • AERSCHOT AV: Oligonucleotides as antivirals: dream or realistic perspective? Antiviral Res. (2006) 71(2-3):307-316.
  • BEHLKE MA: Progress towards in vivo use of siRNAs. Mol. Ther. (2006) 13(4):644- 670.
  • TAUCHI T, SUMI M, NAKAJIMA A, SASHIDA G, SHIMAMOTO T, OHYASHIKI K: CL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin. Cancer Res. (2003) 9:4267-4273.
  • VAN DEVENTER SJH, TAMI JA, WEDEL MK: A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut (2004) 53:1646-1651.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.